Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases

Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases

Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear wheth...

Full description

Bibliographic Details
Main Authors: Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda, Stefan Mrđenović, Slobodanka Ostojić-Kolonić, Dominik Lozić, Hrvoje Holik, Sabina Novaković-Coha, Petra Berneš, Ivan Krečak, Martina Morić-Perić, Marino Narančić, Zdravko Mitrović, Toni Valković
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Biomedicines
Subjects:
lymphoma
chronic lymphocytic leukemia
COVID-19
rituximab
obinutuzumab
purine analogues
Online Access:https://www.mdpi.com/2227-9059/12/2/331

Internet

https://www.mdpi.com/2227-9059/12/2/331

Similar Items